Bone Biologics Corporation
BBLGHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Bone Biologics Corporation focuses on Biotechnology services and products. Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. The $1.5M market capitalization puts BBLG squarely in micro-cap range for its industry. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration.
Market Cap
$1.5M
Beta
0.50
P/E (TTM)
—
P/E (Fwd)
-0.84
EPS (TTM)
$-0.28
EPS (Fwd)
$-0.67
ROE
-55.0%
ROA
-33.5%
Cash
$4.0M
Total Debt
$0
Free CF
-$1.7M
52W Change
-71.6%
Annual Financials
Cash vs Debt
Where BBLG stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BBLG finished 53.39% below its 150-day moving average ($1.18) and 58.02% below its 200-day moving average ($1.31). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BBLG overbought or oversold?
At the September 3, 2026 close, BBLG's RSI(14) was 18.7, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Bone Biologics Corporation reports $4.0M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$1.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -55.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.50 suggests BBLG is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing BBLG's risk profile alongside its fundamentals and technical indicators provides a more complete picture.